Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPCAR01 in Relapsed or Refractory Hepatocellular Carcinoma
NCT06968195Phase 1Suspended
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2026
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT011 in hepatocellular carcinoma (HCC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 30 days, Recommended Phase 2 Dose at 30 days and 2 more. Started Nov 2026; status: suspended.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06968195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968195.